Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?

被引：0
作者：
Han, B. [1 ]
Zhang, B. [1 ]
Xu, J. [1 ]
Zhang, Y. [1 ]
Zhang, X. [1 ]
Chu, T. [1 ]
Wang, S. [1 ]
Qiao, R. [1 ]
Qian, J. [1 ]
Lu, J. [1 ]
Zhang, L. [1 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK; ros1; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-29
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [31] Patients Harboring ALK Rearrangement Adenocarcinoma after Acquired Resistance to Crizotinib and Transformation to SCLC: A Case Report
    Wang, W.
    Xu, C.
    Zhu, Y.
    Liao, X.
    Zhuang, W.
    Du, K.
    Chen, R.
    Chen, Y.
    Chen, G.
    Fang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2244 - S2244
  • [32] CRIZOTINIB THERAPY FOR PATIENTS WITH ADVANCED ROS1-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC)
    Ou, Sai-Hong I.
    Kim, Dong-Wan
    Camidge, D. Ross
    Riely, Gregory
    Salgia, Ravi
    Shapiro, Geoffrey
    Solomon, Ben
    Engelman, Jeffrey A.
    Kwak, Eunice L.
    Clark, Jeffrey W.
    Tye, Lesley
    Wilner, Keith
    Usari, Tiziana
    Varella-Garcia, Marileila
    Bergethon, Kristin
    Iafrate, A. J.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S295 - S295
  • [33] Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report
    Zhang, Yaping
    Wang, Hui
    Wang, Xiaoyan
    Li, Shuai
    Fang, Hongming
    CLINICAL LUNG CANCER, 2021, 22 (05) : E699 - E702
  • [34] CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer
    Zhang, Meiling
    Wang, Qian
    Ding, Yan
    Wang, Guoqun
    Chu, Yunqian
    He, Xiang
    Wu, Xue
    Shao, Yang W.
    Lu, Kaihua
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : 1792 - 1797
  • [35] ROS-1 rearranged bronchopulmonary adenocarcinoma revealed by a pulmonary miliary
    Brindel, Aurelien
    Huet, Dimitri
    Vaillant, Pierre
    Vignaud, Jean-Michel
    Tiotiu, Angelica
    BULLETIN DU CANCER, 2018, 105 (06) : 549 - 551
  • [36] CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer
    Zhang, M.
    Wang, Q.
    Ding, Y.
    Wang, G.
    Chu, Y.
    He, X.
    Wu, X.
    Shao, Y. W.
    Lu, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S800 - S800
  • [37] Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib
    Liu, Yutao
    Liu, Tianfeng
    Li, Nan
    Wang, Tao
    Pu, Yue
    Lin, Rui
    LUNG CANCER, 2019, 129 : 92 - 94
  • [38] Intestinal metastasis from primary ROS1 -positive lung adenocarcinoma cancer patients responding to crizotinib
    Chen, Hua-fei
    Zhang, Qu-xia
    Zhu, You-cai
    Du, Kai-qi
    Li, Xiao-feng
    Wu, Li-xin
    Wang, Wen-xian
    Xu, Chun-wei
    ONCOTARGETS AND THERAPY, 2018, 11 : 7821 - 7825
  • [39] Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement
    Caliez, J.
    Monnet, I.
    Pujals, A.
    Rousseau-Bussac, G.
    Jabot, L.
    Boudjemaa, A.
    Leroy, K.
    Chouaid, C.
    REVUE DES MALADIES RESPIRATOIRES, 2017, 34 (05) : 576 - 580
  • [40] Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma
    Zito Marino, Federica
    Morabito, Alessandro
    Gridelli, Cesare
    Rocco, Gaetano
    Liguori, Giuseppina
    De Rosa, Nicla
    Botti, Gerardo
    Franco, Renato
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (09) : E86 - E88
12345